Ekso Bionics reports record Q4 revenue $5.1M, net loss improves 25% for FY 2024

EKSO BIONICS HOLDINGS, INC.

Q4 2024 revenue $5.1M, up 5% YoY; gross margin 53%, up 400 bps vs 49% in Q4 2023.
FY 2024 revenue $17.9M, down 2% YoY; net loss $11.3M ($0.56/sh), 25% better than FY 2023.
Cash and restricted cash $6.5M at Dec 31, 2024; operating cash burn improved to $9.8M from $12.1M.
Post-year-end, named National Seating & Mobility exclusive U.S. distributor for Ekso Indego Personal device.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.